- Conditions
- IgA Nephropathy
- Interventions
- Telitacicept 160mg, Telitacicept 240mg, Placebo
- Drug
- Lead sponsor
- RemeGen Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Sacramento, California • San Francisco, California + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Immunoglobulin A Nephropathy, Healthy Subjects
- Interventions
- Fish Oil
- Dietary Supplement
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Davis, California
- Conditions
- pMN, IgAN, Nephrotic Syndrome, MCD, FSGS
- Interventions
- Atacicept
- Drug
- Lead sponsor
- Vera Therapeutics, Inc.
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Brisbane, California
- Conditions
- Lupus Nephritis, Immunoglobulin A Nephropathy
- Interventions
- Ravulizumab, Placebo, Background Therapy
- Drug · Other
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 17
- States / cities
- San Dimas, California • Santa Monica, California • South Gate, California + 13 more
- Conditions
- Diabetic Nephropathies, Primary Focal Segmental Glomerulosclerosis, Minimal Change Disease, Primary Immunoglobulin A Nephropathy, Primary Membranous Nephropathy
- Interventions
- WAL0921, Placebo
- Drug
- Lead sponsor
- Walden Biosciences
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Denver, Colorado • Tamarac, Florida + 5 more
- Conditions
- Immunoglobulin A Nephropathy, Glomerular Disease, IgAN
- Interventions
- Dose-Placebo, Low Dose-VIS649, Medium Dose-VIS649, High Dose-VIS649
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 155 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Los Angeles, California • Oxnard, California + 13 more
- Conditions
- Kidney Diseases, Kidney Failure, Chronic, Diabetic Nephropathy, Lupus Nephritis, Glomerulonephritis, IGA
- Interventions
- Not listed
- Lead sponsor
- The Rogosin Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- IgA Nephropathy
- Interventions
- Sibeprenlimab
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 4
- States / cities
- Denver, Colorado • Boston, Massachusetts • Dakota Dunes, South Dakota + 1 more
- Conditions
- Primary IgA Nephropathy
- Interventions
- LNP023
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 448 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 14
- States / cities
- Glendale, Arizona • San Diego, California • San Dimas, California + 11 more
- Conditions
- IgA Nephropathy, Immunoglobulin A Nephropathy
- Interventions
- BION-1301, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 383 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 28
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • San Francisco, California + 24 more
- Conditions
- Primary Immunoglobulin A Nephropathy (IgAN)
- Interventions
- iptacopan
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 5
- States / cities
- Madera, California • Aurora, Colorado • Gainesville, Florida + 2 more
- Conditions
- IgA Nephropathy (IgAN), Berger Disease
- Interventions
- Atacicept
- Drug
- Lead sponsor
- Vera Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Brisbane, California
- Conditions
- Lupus Nephritis, Immunoglobulin A Nephropathy, Membranous Nephropathy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- Interventions
- Povetacicept
- Drug
- Lead sponsor
- Alpine Immune Sciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 18
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Valencia, California + 14 more
- Conditions
- IgA Nephropathy
- Interventions
- Intravenous Rituximab, ACE/ARB, Omega-3 Fatty Acid Fish Oil Supplement
- Drug · Dietary Supplement
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 5
- States / cities
- San Francisco, California • Rochester, Minnesota • New York, New York + 2 more
- Conditions
- IgA Nephropathy (IgAN)
- Interventions
- Avacopan, Prednisone, Methylprednisolone (drug), Prednisolone
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 2
- States / cities
- Jacksonville, Florida • Rochester, Minnesota
- Conditions
- Immunoglobulin A Nephropathy (IgAN)
- Interventions
- ARGX-121, Placebo
- Biological
- Lead sponsor
- argenx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 4
- States / cities
- Miami, Florida • Houston, Texas • Manassas, Virginia
- Conditions
- Immunoglobulin A Nephropathy
- Interventions
- sparsentan, irbesartan, Dapagliflozin
- Drug
- Lead sponsor
- Travere Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 406 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 40
- States / cities
- Birmingham, Alabama • Homewood, Alabama • Glendale, California + 34 more
- Conditions
- IgA Nephropathy, Proteinuria
- Interventions
- Acthar 80 unit injection
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- IgA Nephropathy (IgAN), Renal and Urinary Disorders, Berger Disease
- Interventions
- Atacicept 150 mg
- Drug
- Lead sponsor
- Vera Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 750 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 1
- States / cities
- Brisbane, California
- Conditions
- Immunoglobulin A Nephropathy
- Interventions
- Sibeprenlimab 400 mg, Placebo
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 530 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 54
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 39 more
- Conditions
- Immunoglobulin A Nephropathy
- Interventions
- Sibeprenlimab 400 mg s.c. Q4weeks
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 12 more
- Conditions
- Immunoglobulin A Nephropathy
- Interventions
- Povetacicept, Placebo (matched to Povetacicept)
- Drug
- Lead sponsor
- Alpine Immune Sciences Inc, A Subsidiary of Vertex
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 605 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 77
- States / cities
- Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 67 more
- Conditions
- Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
- Interventions
- CCX168, Midazolam, Celecoxib, Itraconazole, Rifampicin
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Immunoglobulin A (IgA) Nephropathy
- Interventions
- Felzartamab, Placebo
- Drug · Other
- Lead sponsor
- HI-Bio, A Biogen Company
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 4
- States / cities
- Oxnard, California • Vacaville, California • Rochester, Minnesota + 1 more